Hemeo key facts
as of Oct 2026- Developer of a clinical decision support platform designed for blood coagulation management.
- Hemeo is valued at approximately $65.8M as of Oct 2026 (last reported valuation).
- It has raised $8.1M; the latest was Later Stage VC ($15.0M) in Oct 2026.
- Notable investors include NLC Health Ventures, Health Engine Accelerator, ScaleNL, Yahara Software.
- Status: Privately Held (backing).
Hemeo's last reported valuation, Oct 2026. Nothing priced has surfaced since.
- ·Watch Hemeo: the Monday email on marks, rounds and moves
Hemeo funding rounds
No funding rounds for Hemeo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hemeo valuation
Hemeo's last reported valuation was $65.8 million in Oct 2026. No priced round, secondary trade or fund mark has surfaced since.
Hemeo investors
4 investors are on record for Hemeo, including NLC Health Ventures, Health Engine Accelerator, ScaleNL and Yahara Software.
About Hemeo
Developer of a clinical decision support platform designed for blood coagulation management. The company's platform consolidates data from multiple sources in a form that doctors can act on early and with confidence to reduce excess morbidity and death, enabling healthcare providers to improve patients' recovery process and survival rate.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2019
- Employees
- 3
- Website
- hemeo.health/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.